Expression of Cystatin SN significantly correlates with recurrence, metastasis and survival duration in surgically resected non-small cell lung cancer patients
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/srep08230.pdf
Reference23 articles.
1. Siegel, R. et al. Cancer statistics, 2013. CA Cancer J Clin 63, 11–30 (2013).
2. Le Pechoux, C. et al. Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer. Cancer 76, 530–531 (1995).
3. Williams, B. A. et al. Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg 81, 1021–1027 (2006).
4. Scott, W. J. et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132, 234S–242S (2007).
5. Barrett, A. J. The cystatins: a diverse superfamily of cysteine peptidase inhibitors. Biomed Biochim Acta 45, 1363–1374 (1986).
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Cystatin SN (CST1) Is a Poor Independent Prognostic Biomarker for Gastrointestinal Diffuse Large B-cell Lymphoma;Medical Science Monitor;2024-05-30
2. Cysteine protease inhibitor 1 promotes metastasis by mediating an oxidative phosphorylation/MEK/ERK axis in esophageal squamous carcinoma cancer;Scientific Reports;2024-02-29
3. Type 2 Cystatins and Their Roles in the Regulation of Human Immune Response and Cancer Progression;Cancers;2023-11-10
4. SPI1-Mediated Upregulation of the CST1 Gene as an Independent Poor Prognostic Factor Accelerates Metastasis in Esophageal Squamous Cell Carcinoma (ESCC) by Interacting with MMP2;Frontiers in Bioscience-Landmark;2023-09-24
5. Epithelium‐derived cystatin SN inhibits house dust mite protease activity in allergic asthma;Allergy;2023-04-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3